<DOC>
	<DOCNO>NCT00887042</DOCNO>
	<brief_summary>Cord blood transplantation ( CBT ) alternative option patient pediatric acute leukemia indicate stem cell transplantation . Although CBT affective unrelated bone marrow transplantation lower graft versus host disease ( GVHD ) severity incidence , transplantation relate mortality ( TRM ) major problem myeloablative conditioning . To reduce TRM , CBT non-myeloablative conditioning perform satisfactory especially engraftment rate . Recently reduce toxicity myeloablative conditioning regimen develop promise result adult bone marrow mobilize peripheral blood transplantation . To increase engraftment potential low TRM rate , reduce toxicity myeloablative conditioning compose fludarabine , intravenous busulfan plus thymoglobulin plan pediatric patient acute myeloid leukemia .</brief_summary>
	<brief_title>Study Reduced Toxicity Myeloablative Conditioning Regimen Cord Blood Transplantation Pediatric AML</brief_title>
	<detailed_description>Since first successful transplantation use umbilical cord blood ( UCB ) treat patient Fanconi anemia 1988 ( Gluckman E , 1989 ) , cord blood transplantation ( CBT ) become alternative bone marrow transplantation ( BMT ) treat variety disease . Cord blood cell many theoretical advantage graft stem cell transplantation immaturity newborn cell . Compared adult , UCB stem cell produce large vitro hematopoietic colony , able expand long-term culture vitro ( Ahn HS , 2003 ) . The property UCB cell theoretically compensate relatively low number cell obtain single UCB unit , rapid expansion , reconstitute myeloablated patient few nucleated cell ( 1-2 log ) bone marrow ( Barker JN , 2003-1 ) . Recent result CBT reveal HLA-matched 1-antigen mismatch unrelated CBT similar survival HLA-matched unrelated BMT cell dose HLA-disparity influence outcome CBT ( CIBMTR data ) . But major problem CBT engraftment failure transplantation relate mortality ( TRM ) compromise outcomes CBT . As number stem cell low immune cell immature cord blood bone marrow , engraftment immunologic recovery delay CBT BMT property CBT result high rate TRM 39 % 100 day CBT ( Rocha V , 2001 ) . Early result CBT also report upto 50 % TRM ( Gluckman E , 1997 ; Rubinstein P , 1998 ) CIBMTR also report cumulative incidence TRM pediatric study 40 % . As TRM high CBT especially conventional myeloablative conditioning , non-myeloablative conditioning regimen investigate especially adult CBT ( Barker JN , 2003-2 ; Chao NJ , 2004 ) . But study pediatric acute leukemia patient much pilot data suggest CBT non-myeloablative conditioning result low engraftment rate anti-leukemic effect although low morbidity mortality ( Ahn HS , 2004 ) . Recently , fludarabine base reduced toxicity myeloablative regimen investigate promising result adult transplant bone marrow mobilize peripheral blood ( Russell JA , 2002 ; Bornhauser M , 2003 ; de Lima M , 2004 ) . Purine-analog , particular fludarabine , advantage cyclophosphamide . It immunosuppressive property allow engraftment hematopoietic stem cell minimal extramudullary toxicity . Fludarabine also inhibit repair mechanism alkylating agent induce DNA damage , thus provide synergistic effect pre-exposed target tissue . As fludarabine plus myeloablative dose busulfan allow good engraftment reduce toxicity transplant bone marrow mobilize peripheral blood , combination could optimal condition regimen CBT , high TRM low engraftment rate conventional myeloablative conditioning . To increase engraftment potential low TRM rate , reduce toxicity myeloablative conditioning compose fludarabine , intravenous busulfan , thymoglobulin CBT plan pediatric patient AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Diagnosis acute myeloid leukemia ( FAB WHO classification ) . 2 . Indicated hematopoietic stem cell transplantation . 3 . Age : &lt; 21 year old . 4 . Performance status : ECOG 02 . 5 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . 1 . Heart : shortening fraction &gt; 30 % , ejection fraction &gt; 45 % . 2 . Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal . 3 . Kidney : creatinine &lt; 2 × normal creatinine clearance ( GFR ) &gt; 60 ml/min/1.73m2 . 6 . Patients must lack active viral infection active fungal infection . 7 . Appropriate cord blood unit available : accept HLA mismatch two six locus ( pair A , B , DR ) . Allow 2 unit cord transplantation . 8 . One parent sign inform consent . 1 . Pregnant nursing woman . 2 . Malignant ( except acute myeloid leukemia ) nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . 3 . Psychiatric disorder would preclude compliance . 4 . More three HLA type mismatch . 5 . T cell deplete ex vivo expand cord blood .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Cord blood transplantation</keyword>
	<keyword>Pediatric</keyword>
</DOC>